Long-term cardiovascular outcome of renal transplant recipients after early conversion to everolimus compared to calcineurin inhibition:results from the randomized controlled MECANO trial by van Dijk, Marja et al.
  
 University of Groningen
Long-term cardiovascular outcome of renal transplant recipients after early conversion to
everolimus compared to calcineurin inhibition
van Dijk, Marja; van Roon, Arie M; Said, M Yusof; Bemelman, Frederike J; Homan van der






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Final author's version (accepted by publisher, after peer review)
Publication date:
2018
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
van Dijk, M., van Roon, A. M., Said, M. Y., Bemelman, F. J., Homan van der Heide, J. J., de Fijter, H. W., ...
Sanders, J. S. F. (2018). Long-term cardiovascular outcome of renal transplant recipients after early
conversion to everolimus compared to calcineurin inhibition: results from the randomized controlled
MECANO trial. Transplant International, 31(12), 1380-1390. https://doi.org/10.1111/tri.13322
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the











This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which may 
lead to differences between this version and the Version of Record. Please cite this article as 
doi: 10.1111/tri.13322 
This article is protected by copyright. All rights reserved. 
MRS. MARJA  VAN DIJK (Orcid ID : 0000-0002-8108-0932) 
 
 
Article type      : Original Article 
 
Long-Term Cardiovascular Outcome of Renal Transplant Recipients after Early Conversion 
to Everolimus Compared to Calcineurin Inhibition: Results from the Randomized Controlled 
MECANO Trial  
2) Running title/short title (max. 40 characters)  
MECANO substudy: Vascular Outcome 
 
3) Authors' names (first names and surnames in full)  
Marja van Dijk1,  Arie M.  van Roon2,  M. Yusof Said1,  Frederike J.  Bemelman3,  Jaap J. 
Homan van der Heide3,  Hans W. de Fijter4 , Aiko P.J. de Vries4, Stephan J.L. Bakker1, Jan 
Stephan F. Sanders1 
 
4) Authors' affiliations/institutions 
1Department of Internal Medicine, division of Nephrology, University Medical Center 
Groningen, University of Groningen, Groningen, The Netherlands 
2Department of Vascular Medicine, University Medical Center Groningen, University 
of Groningen, Groningen, The Netherlands 
3Renal Transplant Unit, Amsterdam, The Netherlands 
4Department of Nephrology, Leiden University Medical Centre, Leiden, The 
Netherlands. 
 
5) Author roles for each author  
Marja van Dijk:  Performed research, collected data, analyzed data, drafted 
manuscript 
Arie M.  van Roon: Analyzed data and helped with manuscript   
M. Yusof Said:  Analyzed data (Mixed models) 
Frederike J.  Bemelman: Designed research, participated in patient care  
Jaap J. Homan van der Heide:  Designed research, participated in patient care 
Hans W. de Fijter:  Designed research, participated in patient care 
Aiko P.J. de Vries:  Participated in patient care 
Stephan J.L. Bakker: Revised the manuscript  
Jan Stephan F. Sanders : Edited the manuscript  
 
6) Full name and address of corresponding author (including e-mail address)  
Marja van Dijk, Hanzeplein 1, 9700 RB Groningen, The Netherlands 
Tel: +31503610113, Fax: +31503614327, Email: m.van.dijk02@umcg.nl 
 
7) Funding sources (state "no funding" if applicable) 











This article is protected by copyright. All rights reserved. 
8) Conflict of interest statement 
no conflict of interest 
 
9) Keywords 





Long-term data on cardiovascular (CV) outcome of renal transplant recipients (RTR) on 
mTOR-i (mammalian Target Of Rapamycin-inhibitors) are scarce. In a sub-study of the 
MECANO trial we investigated changes in intima media thickness (IMT), CV risk profile, 
Major Adverse CV Events (MACE) and survival  in RTR on a mTORi versus CNI based 
regimen. 
Patients (enrolled 361) were treated with (basiliximab) and triple IS (CsA-Cyclosporine A-(C), 
MPS(M), prednisolone(P)). At M6 patients were randomized (n=224) to the CsA group (C, P, 
N=89), MPS group (M, P, N=39) EVL group (Everolimus, P, N=96). 
At week 2, M6 and M 24, IMT measurements of the Common Carotid Artery were 
performed. Cardiovascular risk factors were assessed at baseline, 6 and 24 months of 
follow-up. Seven years survival and MACE -free survival probability were calculated by the 
Cardiovascular Risk Calculator for RTR. After seven years of follow-up incidence of 
cardiovascular events and patient survival were assessed. Mean IMT at baseline, (N=192), 
was 0.64±0.14 mm.  At M6 (N=158), 0.66±0.15, M24 IMT was 0.68±0.15 (N=95).   
Conclusion:  No significant differences between groups concerning IMT, true CV events and 
mortality, CV risk profile, predicted MACE  / Mortality were found between mTORi and CNI-
based regimen after 7 years of follow-up.  
 
Introduction 
Chronic kidney disease is a major worldwide public health problem. Renal transplantation 
has been established as the optimal  treatment for end stage renal disease. Despite this, 
after renal transplantation long-term life expectancy is limited, which is mostly  due to the 
increased risk of cardiovascular (CV) disease1.   
The introduction of Cyclosporine A (CsA) and other Calcineurin inhibitors (CNI’s) significantly 
improved the outcome of all solid-organ transplants by reducing the risk of rejection.2  
Nevertheless, long term calcineurin inhibitor (CNI)-based immunosuppression is associated 
with nephrotoxicity and other adverse events, including hypertension, hyperlipidemia and 
diabetes mellitus3. Therefore, CNI- sparing regimens have been proposed to improve graft 
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Multiple randomized controlled trials (RCT) have investigated mTOR inhibitors as a potential 
alternative for CNIs, overall resulting in better renal function, but at cost of increased risk of 
rejection4,5.     
However, long term data on outcome, and especially CV outcome in renal transplant 
recipients (RTR) on  mTORi are scarce. 
In the present study, as a sub-study of the MECANO trial,  IMT and change of IMT over time 
were prospectively measured as a CV outcome parameter in RTR. Additionally, we 
assessed cardiovascular risk profile, and compared true long-term CV event-free survival 
and mortality in RTR randomized to a mTORi- versus CNI-based immunosuppressive 
regimenFinally, we aimed to reproduce the previously published cardiovascular risk 
calculator from Soveri et al6 
 
Patients and methods 
Between November 2005 and June 2009 361 de novo kidney transplant patients were 
recruited in three Dutch Transplantation centers to participate in the MECANO trial.  The 
study was conducted according to the Good Clinical Practice guidelines and in accordance 
to the ethical principles of the declaration of Helsinki and was approved by the Dutch 
Medical Ethical Board for medical research.5 (Trial registration NTR1615). All patients gave 
written informed consent. This study was a 24-month, prospective, multi-center, open-label 
randomized controlled trial, aiming at optimizing immunosuppression and reducing side 
effects, including cardiovascular outcome. The quadruple immunosuppressive regimen for 
all patients during the first six months was similar: induction with basiliximab, followed by 
CsA, MPS and prednisolone7.  At month six a protocol biopsy was performed. When no 
histological signs of rejection were seen, patients were randomized to receive dual 
immunosuppressive therapy with either CsA, MPS or Everolimus, all in combination with 
prednisolone.  In case of (borderline) rejection patients were not randomized. For detailed 
description see Bemelman et al.5  Primary endpoint of the MECANO study was the 
development of interstitial fibrosis at the 24-month protocol biopsy5, published in AJT 2016, 
secondary end-points were amongst others CV endpoints; Intima Media Thickness (IMT) of 
the common carotid artery, blood pressure and the number of antihypertensives, lipid profile, 
fasting glucose and HbA1C. The present study reports mentioned secondary endpoints. 
After enrollment of 39 patients, the MPS -arm was prematurely stopped by the Data Safety 
Monitoring Board, because of an unacceptably high rejection percentage (21%). Patients in 
the MPS-arm stayed on MPS when they did well and completed the trial (n=39), the trial 
continued as a two-armed trial, comparing CsA and EVL.  
 
Intima Media-Thickness measurement was performed at approximately day 14 (W2), after 
six months (M6) and after 24 months (M24). The longitudinal axis of the common carotid 
artery was scanned in the supine position, at the right and left side. Acuson 128XP systems 
(Acuson Corporation, Mountain View, CA, USA) with 7.0 MHz ultrasound transducer were 
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Subsequently, all measurements were scored and verified by 2 persons, the inter-observer 
variation was 3.9 %. 
For scoring cardiovascular risk we used the previously described Cardiovascular Risk 
calculator for renal transplant recipients6. Additionally, cardiovascular events and mortality 
data were collected until 7 years after renal transplantation.     
 
Statistical analysis  
To test whether variables were normally distributed, we used the Kolmogorov-Smirnov test. 
Multiple group comparisons were computed with the Kruskal-Wallis Test. To test effects of 
time point (visit), the multivariate Friedman test was used. To compare two time points, 
Wilcoxon Signed Ranks test was used. We calculated ROC-curves using the 7-years events 
and deaths, as previously poublished by Soveri. 
Since the distribution of pMACE and pMort was not normal, we transformed these variables  
to wMACE and wMort, using the logit transformation8,9 , before using the variables in a 
regression analysis. Survival was assessed by Kaplan-Meier estimates for survival 
distribution. Differences between groups in survival were analysed with log-rank tests. 
Statistic tests were performed using SPSS 22.0 (2013, IBM Corp., Armonk, NY, USA).  
Linear mixed model analyses were performed using Stata 14 (2015, StataCorp LP., College 
Station, Texas, USA). We performed all analyses twice: first comparing IMT in the MPS vs. 
CsA vs. EVL groups. Second, we compared IMT in the CsA versus EVL groups. We 
assigned the intercept and slope of the individuals and the medical center of treatment as 
random factors. A scaled identity covariance structure was applied and we assigned all 
predictors as fixed factors. The interaction (calculated as the product) of the study group and 
follow-up time in months (from the first IMT assessment at week 2) was regarded as the 
slope of IMT per group over follow-up time. We adjusted the associations for sex and age 
(model 1) and consequently smoking behavior (never, ex or current) and BMI (model 2).  
P-values below 0.05 were considered significant. 
Results 
In total 224 patients were randomized after renal transplantation.  Of these patients, 89 were 
randomized to the CsA group, 39 to the prematurely stopped MPS- and 96 to the Everolimus 
group.  Patient characteristics did not differ significantly between the three groups (Table 1). 
In total 119 (53%) patients received a kidney from a living donor, 67 (30%) of a DBD 
(donation after brain death), and 37 (17%) of a DCD (donation after cardiac death) donor.  
Mean age at time of transplantation was 51.6, mean donor-age 47.1 years. For those 
patients receiving dialysis, mean total time on renal replacement therapy (TTRRT) was 32 
months. Half of all patients never smoked, 33.6 % were previous smokers and 16.3 % was 
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Intima Media Thickness 
The first IMT in this study was assessed at W2 (n=192) and the mean in all patients was 
0.64 ±0.14 mm. (Fig 1). All IMT measurements are also shown in Table 2. At randomization 
(6 months), the mean IMT in all patients (n=158) was 0.66 ± 0.15 mm. The IMT at six 
months after renal transplantation did not differ significantly between the three treatment 
groups. At 24 months,  IMT was 0.66 (±0.14) mm in the CsA group and 0.66 (±0.13) mm in 
the EVL group, whereas it was 0.76 (± 0.2) mm in the MPS group.(p=0.06) For analysis of 
change in IMT over time, we only used the assessments of 95 patients that had an IMT 
measurement at 24 months. For all these patients measurements were available at 2 weeks 
and 6 months after transplantation (Fig 2). No significant differences were observed in 
change of IMT over time after renal transplantation.  
We also analyzed subgroups of patients for differences in IMT change. Neither RTR 
transplanted  with a living versus deceased donor, nor patients who were transplanted pre-
emptively versus those transplanted after start of renal replacement therapy, showed 
significant differences in change of IMT over time. 
Patients who developed a CV event during the study (24) and in whom IMT was measured 
(n = 23), did not have significant higher IMT at baseline as compared to patients who did not 
suffer from a CV event. (p=0.26).  Also, the change in IMT – a decrease of 0.03 mm in 
patients suffering of a cardiovascular event (n=11) and an increase of 0.06 mm in patients 
who died (n=10) - was not significantly higher, than in patients who did not develop a CV-
event.   
Finally, we performed a mixed model analysis comparing IMT. In the first analysis we 
compared the CSA, EVL and MPS groups: no significant association was found between 
treatment arm and IMT slope over follow-up time (supplementary Table S1: β [95%CI]: 
0.0001 [-0.003–0.003], CsA: p = 0.96; EVL: -0.0004 [-0.0003–0.003], p=0.78, MPS: 
reference. Adjusted for age, sex, BMI, and smoking behavior). A significant positive 
association was found of age (β [95%CI]: 0.005 [0.004–0.007],  (p <0.001) and a history of 
smoking (β [95%CI]: 0.04 [0.003–0.07], (p = 0.03),  with mean IMT over the follow-up period. 
In the second analysis we compared CSA and EVL groups but no significant differences 
were found between these two treatment groups in IMT slope (supplementary Table S2: 
EVL: β [95%CI]: -0.0004 [-0.002–0.002], p = 0.69; EVL: reference. Adjusted for age, sex 
BMI, and smoking behavior). Similarly,  age (β [95%CI]: 0.005 [0.004–0.006], p<0.001) and 
a history of smoking (β [95%CI]: 0.06 [0.03–0.09], p = 0.001) were associated with mean 
IMT over time. 
Cardiovascular risk factors  
Systolic blood pressure, as well as diastolic blood pressure in all groups remained stable, no 
significant differences were found between the three groups at any moment.  
The total number of antihypertensive (AH) agents decreased immediately after 
transplantation, but increased towards 6 months, and at 2 years after transplantation  the 
number of prescribed AH was 2.1 (mean), but this was not significantly more than at two 
weeks after renal transplantation, and did not differ significantly between the three treatment 
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BMI increased significantly in all patients both from week two (25.2) to month 6 (26.1) and 
again from month 6 to month 24 (26.9). However, between the groups, no significant 
differences were found. 
Also, HbA1c values increased significantly over time, but did not differ between the 
randomization groups. In concordance herewith, fasting  glucose levels increased over time 
and were  significantly (p<0.05) higher at 24 months after renal transplantation than all 
previous measurements for all patients.  Again, no differences between the three groups 
were found.  
For total-cholesterol levels, a significant (p< 0.005) increase over the total cohort was found. 
These levels increased from 4.2 mmol/l at start to 5.1 mmol/l  at 24 months after 
transplantation. However, LDL cholesterol levels did not change over time. In both total- and 
LDL-cholesterol levels no differences were found between the 3 groups. The use of  statins 
increased significantly from 44.8% at baseline, towards in 68.8 % at 24 months in all 
patients.  
Cardiovascular events  and mortality 
The chance to suffer from a major adverse cardiac event was predicted by the previously 
validated pMACE score. The pMACE score did not differ between the groups and was 10% 
in the CsA group, 11% in the MPS and 12% in the EVL-group. 
After 7 years of follow-up a  CV event occurred in 11% of the patients of CsA group, 16% in  
the MPS group and 10% in the EVL group , and did not differ significantly between groups 
(p=0.58).   Patients with a CV event had a higher pMACE than patients without (0.15 vs. 
0.10, p=0.009).  IMT and transplant function were not different between patients with and 
without a CV event.  (IMT: p=0.26, MDRD: p=0.41). 
 
The predicted chance to die within 7 years was 13, 15 and 15% respectively. Overall, nine 
patients (10%) died in the CsA group, six patients (15%) in the MPS and 16 (17%) in the 
EVL group. ((p= 0.42)  Table 3). Patients who died had a higher pMort than patients who did 
not (0.13 vs. 0.22, p<0.001). Of the 31 patients who died within 7 years, four had a 
cardiovascular event, 25 did not and in two patients the cause of death was unknown. 
However, in 60 % of  patients who died the cause of death was registered as “not 
determined”, so a cardiovascular cause cannot be fully excluded. Eventually, both the 
incidence of cardiovascular events and mortality rate did not differ significantly between the 
three treatment groups . (Fig 3) 
 
Replication ROC-curves of Soveri et. al.6 
We calculated ROC-curves using the 7-year events and deaths (Figure 4). These values 
correspond to previous results performed by Soveri et al. 
The area under the curve for MACE was 0.70 (95% confidence interval 0.534-0.860). For 
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Discussion  
It is well established that renal transplantation is the optimal treatment option for patients 
with renal insufficiency. However, also after renal transplantation the risk of cardiovascular 
events and the overall mortality is increased as compared to the population as a whole. It is 
hypothesized that the choice of immunosuppressive drug might influence the long-term 
outcome. However, the results of our study show that the long-term cardiovascular risk as 
evaluated  by CV risk factors, IMT (as a marker of CV disease),  calculated risk of CV events 
(pMACE) and the occurrence of CV events up to seven years after RT , did not differ in 
kidney transplant recipients on mTORi or CsA. 
Scarce evidence is available concerning kidney transplantation and the alleged profit of 
mTORi  in relation to long-term outcome.  As shown in 2005,  kidney transplant patients with 
poor renal function have a higher risk of all- cause and CV death10.   The Five-year 
outcomes after conversion from CsA to Everolimus; the randomized ZEUS study11 showed a 
significant improvement in renal function that is maintained to at least 5 years. In a 
systematic review and meta-analysis of individual patient data by Knoll et al a higher 
mortality rate was found in renal transplant recipients (RTR)  on the mTORi sirolimus.12 Also, 
a retrospective analysis of the United States Renal Data System (USRDS) by Isakova et al13 
found a higher mortality rate in association with sirolimus. However, these registry data 
should be interpreted with care due to, among others, temporal trends and indication bias. 
Regarding everolimus, a recent long-term study by Lim et al combining everolimus with 
reduced CsA versus mycophenolate sodium with standard CsA did not find differences in 
mortality rate or graft loss between the study arms 14.   
Additionally, Knoll et al reported higher mortality rates with higher everolimus trough levels 
(defined > 10 ng/ml). Also, in our study mean trough levels were higher than in more recent 
CNI- conversion or CNI-combination studies, which might explain higher discontinuation 
rates.  
 
At the time of designing the present study, Intima Media Thickness was considered the best 
non-invasive sonographic marker for early atherosclerosis vascular wall lesions15. In a 
community-based cohort study it was found that impairment in kidney function was 
associated with adverse changes in arterial structure in a general elderly population. These 
changes occurred in an early stage of deterioration of kidney function, and they were 
predictors of cardiovascular outcome16.   
In a previous study in a cohort with early stage chronic kidney disease, a median IMT of 0.6 
mm  (0.4-0.7 mm) was found17.   
A comparison of IMT in dialysis and kidney transplant recipients patients showed that IMT in 
dialysis patients was significantly higher compared to kidney transplant recipients, and IMT 
increased with longer duration of dialysis18. 
Due to beneficial results with Everolimus, amongst others seen in heart transplantation19, we 
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differ significantly between groups, nor did it change over time. No association was found 
with the occurrence of cardiovascular events during long-term follow-up. Additional analyses 
by mixed models showed associations of IMT with age and smoking status but not with 
immunosuppressive therapy. In conclusion, IMT measurement was not of added value in 
detection of patients at increased risk for cardiovascular events after renal transplantation. 
That result seems to be inconsistent with earlier findings in both the general population and 
CKD patients.20  
In another  study in which 17 patients were converted from CsA to everolimus, Pulse Wave 
Velocity increased significantly in the 10 patients who continued CsA group between 6 and 
15 months, whereas  a slight decrease (ns) was found in the Everolimus group.21 However, 
recently the 2 years results from the ELEVATE study were published and suggested that 
conversion from CNI to everolimus at 10-14 weeks after kidney transplantation is not 
associated with ventricular mass index and pulse wave velocity.22  So currently available 
evidence does not suggest clinically relevant differences between CNI and mTORi on these 
cardiovascular endpoints in renal transplant recipients.  
Regarding the cardiovascular risk profile the patients included in our trial had an elevated 
blood pressure, cholesterol and glucose-level. Although statin use increased from 45% to 69 
% of the patients LDL cholesterol did not reach target levels < 2.5 mmol/L. Nowadays statins 
are advised by protocol for all recipients of renal transplantation (KDIGO Guideline for the 
Care of Kidney Transplant Recipients, Dyslipidemia).23  Between the CsA and EVL groups 
no significant differences were found in cardiovascular risk profile. Also, the ELEVATE study 
in which cardiovascular parameters were studied in patients after an early switch to 
everolimus (mean trough level of everolimus throughout the study 7.2 ng/mL) or remaining 
on CNI, showed no significant difference in cardiovascular parameters, nor in mortality rate 
22,24.  And, in a study from Spagnoletti, in which patients were assigned to either 
tacrolimus/MMF, or Everolimus/ low CsA,  cardiovascular risk profiles were similar, although 
the latter group showed significantly higher dyslipidemia.25 In this study the use of 
antihypertensive agents was similar between CsA- and TAC-based regimen. However, 
although the number of deaths in our study due to cardiovascular causes was low, it cannot 
be excluded that these were underreported in the registry. Nevertheless, our study results 
emphasize the importance of adequate cardiovascular risk management in this high risk 
population.  
The Cardiovascular Risk calculator for renal transplant recipients was published in 2012, and 
we were able to evaluate the occurrence of  CV events and death 7 years after renal 
transplantation,  thereby reproducing the Risk calculator predictions.  In our study with 7 
years follow-up the incidence of cardio vascular events and mortality was high, as expected 
in this high risk population. However, no difference between mTORi and CNI was found. In 
the ALERT study from which the Cardiovascular Risk calculator was derived the majority of 
patients used prednisolone and/or azathioprine. As only a small subgroup used modern 
immunosuppressive drugs as CNI, mTORi and mycophenolic acid, thus far it was not clear 
whether this tool was able to predict mortality or CV events dependent on the choice of 
immunosuppression. Hereafter, MACE and mortality risk calculator have been externally 
validated and found suitable in the BENEFIT and BENEFIT-EXT trials, including belatacept 
and CsA treated patients26. Now, the ROC-curves in the current study including mTORi 
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this cardiovascular risk calculator seems to predict cardiovascular risk independent of the 
choice of immunosuppressive drug. 
This study shows that in this fairly low risk cohort of Dutch patients the use of Everolimus is 
neither superior nor inferior to the use of CsA, in relation to CV outcome, so both regimes 
can  be used safely.The current study had several limitations. The MPS arm was stopped 
prematurely, so limited data for this group were available.  Secondly, between performing 
IMT assessments and actual scoring and analysis of IMT-data a long time passed by due to 
several and various personnel- and software problems. Finally, between IMT measurement 
at 24 months and subsequent follow-up a period of max 5 years could have been passed. 
This could have led to disparity between the IMT measurements and the occurrence of these 
events.  Additionally,  due to technical failure,  in one of the centers at 24 months no 
appropriate measurements of IMT were performed.  Therefore IMT- data at 24 months were 
limited to two centers.  Due to study design only CsA was included, and Tacrolimus-based 
immunosuppression was not evaluated. Obviously, this could have impacted the outcomes 
of our study on cardiovascular events and especially hypertension, as CsA is associated 
with different side effects as compared to tacrolimus.  Currently, CNIs are also more often 
combined with mTORi, however, this regimen was not studied in this RCT. Furthermore, the 
endpoint of the MECANO study was powered on renal function, CV outcome was a 
secondary endpoint. Finally, the study size was limited and after seven years only a limited 
number of patients used the initial immunosuppressive regimen, resulting in a limited 
sensitivity for detecting differences in the occurrence of cardiovascular events between the 
treatment groups.   
In conclusion: 
In depth, cardiovascular risk profiling by the measurement of IMT, and traditional 
cardiovascular risk factors,  as well as long-term follow-up over a period of seven years of 
CV events, this study did not show significant differences in any CV surrogate or true 
endpoints between RTR on prednisolone with CsA, with MPS or with EVL.  Therefore,  
based on CV risk profile, choice of immunosuppressive regimen seems not warranted. 
Additionally, we conclude that measurement of IMT did not contribute to CV-risk profiling, 
whereas pMACE predicted the occurrence of cardiovascular events.  Further studies and 
adherence to current cardiovascular guidelines are needed to further improve CV outcome 
of this high risk population. 
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Table 1: Baseline characteristics of randomized patients 
361 patients were enrolled, but 137 did not continue on assigned treatment, so 224 randomized 
patients remained. 
Variable, mean (sd) or % CsA/P MPS/P EVL/P Total 
Number of randomized patients 89 39 96 224 
Age (yr) 49.7 (12.7) 53.7 (11.3) 51.4 (12.8) 51.1 (12.5) 
Sex (% Male) 62.9 64.1 64.6 63.8 
First transplant (%) 95.5 92.3 93.8 94.2 
Cause (%)     
Diabetes mellitus 2.2 5.1 4.2 3.6 
Hypertension 14.6 23.1 15.6 16.5 
Glomerulonephritis 19.1 12.8 17.7 17.4 
Pyelonephritis or interstitial nephritis 3.4 0.0 3.1 2.7 
Focal segmental glomerulosclerosis 3.4 5.1 4.2 4.0 
Urologic 5.6 5.1 10.4 7.6 
Polycystic Kidney Disease 23.6 23.1 20.8 22.3 
Vascular 4.5 5.1 5.2 4.9 
Other 23.6 20.5 18.8 21.0 
Donor type (%)     
Deceased after brain death 25.8 41.0 29.5 30.0 
Deceased after cardiac death 14.6 17.9 17.9 16.6 
Living related 25.8 15.4 22.1 22.4 
Living unrelated 33.7 25.6 30.5 30.9 
Donor age (yr) 48.7 (13.7) 43.4 (15.8) 49.3 (12.8) 48.1 (13.8) 
Antigen mismatch (n) 2.8 (1.5) 2.8 (1.8) 2.9 (1.5) 2.8 (1.6) 
Cold ischemia time (hr)     
Living 2.4 (0.6) 2.4 (0.6) 2.8 (2.3) 2.6 (1.5) 
Deceased 17.2 (4.8) 16.1 (5.6) 15.6 (5.2) 16.3 (5.2) 
TTRRT (month) 27.7 (28.9) 33.4 (31.1) 35 (33.5) 31.8 (31.4) 
Smoking (%)     
Never 48.3 48.7 53.1 50.4 
Previous 34.8 35.9 30.2 33.0 
Current 16.9 15.4 16.7 16.5 
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Table 2: Outcome parameters 
Group  CsA/P  MPS/P  EVL/P pGroups  Total 
Variable N mean (sd) N mean (sd) N mean (sd)  N mean (sd) 
IMT [mm]          
At wk 2 81 0.62 (0.12) 30 0.71 (0.19) 81 0.64 (0.14) 0.12 192 0.64 (0.14) 
At mo 6 69 0.64 (0.15) 22 0.72 (0.22) 67 0.65 (0.12) 0.35 158 0.66 (0.15) 
At mo 24 39 0.66 (0.14) 17 0.76 (0.20) 39 0.66 (0.13) 0.06 95 0.68 (0.15) 
SBP [mmHg]          
At wk 2 77 146 (20) 28 143 (18) 79 143 (19) 0.56 184 144 (19) 
At mo 6 80 141 (18) 30 143 (26) 76 146 (19) 0.11 186 143 (20) 
At mo 24 67 143 (22) 24 146 (20) 64 140 (17) 0.37 155 142 (20) 
DBP [mmHg]          
At wk 2 77 85 (11) 28 82 (  9) 79 84 (12) 0.41 184 84 (11) 
At mo 6 80 84 (11) 30 82 (13) 76 86 (13) 0.25 186 84 (12) 
At mo 24 67 85 (12) 24 81 (12) 64 81 (10) 0.10 155 83 (11) 
BMI [kg/cm²]          
At wk 2 76 24.9 (3.7) 28 26.2 (3.6) 80 25.2 (3.8) 0.33 184 25.2 (3.7) 
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At mo 6 81 125.0 (31.8) 30 112.4 (37.4) 81 125.9 (40.6) 0.19 192 123.4 (36.7) 
At mo 24 78 140.6 (46.2) 29 120.4 (43.7) 81 138.2 (59.6) 0.13 188 136.4(52.3)** 
HbA1c [mmol/mol]          
At baseline 73 43.0 (11.8) 27 43.2 (10.2) 71 41.1 (9.9) 0.66 171 42.3 (10.8) 
At wk 2 71 42.5 (10.7) 29 41.9 (9.0) 74 40.2 (8.9) 0.48 174 41.4 (9.7)‡ 
At mo 6 76 42.5 (11.7) 30 47.7(17.6) 77 42.5 (9.2) 0.51 183 43.4 (12) 
At mo 24 67 42.9 (9.7) 24 44.7(11.9) 69 44.7 (9.4) 0.34 160    44.0 (9.9)# 
Glucose [mmol/l]          
At baseline 74 5.3 (1.2) 24 5.9 (2.0) 72 5.3 (1.0) 0.43 167 5.4 (1.3) 
At wk 2 72 5.3 (1.3) 25 6.5 (5.3) 72 5.5 (1.7) 0.53 169 5.6 (2.5) 
At mo 6 76 5.5 (1.6) 25 6.2 (3.2) 74 5.5 (1.7) 0.35 175 5.6 (1.9) 
At mo 24 68 5.6 (1.7) 25 6.2 (2.5) 68 6.2 (2.2) 0.12 161 6.0 (2.1)‡ 
Cholesterol 
[mmol/l] 
         
At baseline 73 4.3 (1.2) 22 3.9 (0.7) 71 4.3 (1.0) 0.38 167 4.2 (1.1) 
At mo 6 78 5.2 (1.0) 30 4.8 (0.8) 80 5.1 (1.0) 0.11 188 5.1 (1.0)** 
































LDL [mmol/l]          
At mo 6 79 3.1 (0.9) 27 2.8 (0.8) 80 3.1 (0.9) 0.17 186 3.1 (0.9) 
At mo 24 68 2.9 (0.8) 25 2.8 (0.8) 71 3.0 (0.9) 0.49 164 3.0 (0.9)* 
Anti-hypertensives 
 
         
At baseline 81 2.07 (1.37) 30 1.53 (1.33) 81 1.98 (1.15) 0.10 192 1.95 (1.28) 
At wk 2 81 1.42 (0.96) 30 1.23 (0.86) 81 1.30 (0.86) 0.70 192 1.34 (0.90)** 
At mo 6 81 1.80 (0.98) 30 1.77 (0.82) 81 1.98 (1.01) 0.42 192 1.87 (0.97)** 
At mo 24 81 2.11 (1.08) 30 1.77 (0.94) 81 2.16 (1.10) 0.16 192 2.08 (1.07)** 
Statin use   percentage  percentage  percentage   percentage 
At baseline 81 43.2% 30 50.0% 81 44.4% 0.81 192 44.8% 
At mo 6 81 61.7% 30 53.3% 81 54.3% 0.57 192 57.3%** 
At mo 24 81 74.1% 30 50.0% 81 70.4% 0.05 192 68.8%+## 
Diuretics use   percentage  percentage  percentage   percentage 
At baseline 72 52.8% 26 88.5% 67 55.2% 0.004 165 59.4% 
At wk 2 72 84.7% 26 88.5% 67 80.6% 0.62 165 83.6%** 
At mo 6 72 75.0% 26 73.1% 67 65.7% 0.47 165 70.9%*# 
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* p<0.05 significant change from previous time point, ** p<0.005 significant change from previous time point  
# p<0.05 significant change from baseline, ## p<0.005 significant change from first time point 
‡ p<0.05 significant change from all other time points  
pGroups: p-value for test of group differences (Kruskal Wallis test) 
IMT: Intima Media Thickness 
SBP: Systolic Blood Pressure 
DBP: Diastolic Blood Pressure 
LDL: Low Density Lipoprotein 
To test the variables if they are normally distributed, we used the Kolmogorov-Smirnov test. Group comparisons are tested with the Kruskal-Wallis Test. To test effects of time point (visit), we used 
the Friedman test. To compare two time points, we used Wilcoxon Signed Ranks test. Tests with p-values below 0.05 are considered significant.  
 
 
Table 3: Events at 7 years post TX and risk scores at baseline 
 
Event, risk CsA/P MPS/P EVL/P Total P-value 
Number of CV events (%) 9 (11) 6 (16) 9 (10) 24 (11) 0.58 
Number of death (%) 9 (10) 6 (15) 16 (17) 31 (14) 0.30 
pMACE06 (max) 0.10 (0.47) 0.11 (0.32) 0.12 (0.45) 0.11 (0.47) 0.47 
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Excluded (n=137)  
- Not meeting inclusion criteria (n=54)  
- Consent withdrawn (n=59)  
- Graft loss (n=16)  
- Deceased (n=7)  
- Other reasons (n=1) 
     
        Enrolled: 361 
M6 
Randomized  (n=224) 
24M IMT measurements 
(n=17) 
         
CsA (n=89) 
- completed (n=74) 
- Not completed (n=15) 
- Change in regimen (n=6) 
-Regimen intolerability (n=1) 
-Consent withdrawn (n=4) 
-Graft loss (n=3) 
-Deceased (n=1) 
 
IMT measurements M6 (n=69) 
24M IMT measurements  (n=39) 
 
MPS (n=39)  
 
Study arm halted after inclusion 
of 39 patients.,  
IMT measurements M 6 (n=22)  
EVL (n=96)  
- completed (n=59)  
- Not completed (n=37)  
- Change in regimen (n=26)  
- Regimen intolerability (n=1)  
- Consent withdrawn (n=7)  
- Deceased (n=4) 
 
IMT measurements M6 (n=67) 
(n=67) 
24 M   IMT measurements 
(n=39) 
    
         
Follow-up data at 7 year,    n: 
 
CV event CsA  9 
  MPS  6 
  EVL  9 
 
Died  CsA  9 
  MPS  6 
  EVL 16 
 
Graft loss CsA     8 
  MPS    4 
  EVL     6 
 










In trial at M24  
(n=217, with IMT n=95) 
(n =17) 
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Figure 4: Receiver operating characteristics for major adverse cardiac event (A) and for mortality (B)
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